Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
This study has been completed.
Study NCT00000626 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: November 2, 1999 Last Updated: June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Hodgkin's Disease
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Hodgkin Disease
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Immunoproliferative Disorders
Lentivirus Infections
Lymphatic Diseases
Lymphoma
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Vinblastine sulfate
Dacarbazine
Filgrastim
Bleomycin sulfate
Doxorubicin hydrochloride
Additional drug interventions recognized in this trial
Bleomycin
Doxorubicin
Vinblastine
More general drug interventions related to this trial
Alkylating Agents
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Amgen
National Institute of Allergy and Infectious Diseases (NIAID)
Back to top of Main Content
